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a b s t r a c t
Quinoxaline derivatives are an important class of heterocycle compounds, where N replaces some carbon
atoms in the ring of naphthalene. Its molecular formula is C8H6N2, formed by the fusion of two aromatic
rings, benzene and pyrazine. It is rare in natural state, but their synthesis is easy to perform.
In this review the State of the Art will be presented, which includes a summary of the progress made
over the past years in the knowledge of the structure and mechanism of the quinoxaline and quinoxaline
derivatives, associated medical and biomedical value as well as industrial value.
Modifying quinoxaline structure it is possible to obtain a wide variety of biomedical applications,
namely antimicrobial activities and chronic and metabolic diseases treatment.1. Introduction
Quinoxaline derivatives are an important class of heterocyclic
compounds, in which N replaces one or more carbon atoms of the
naphthalene ring [1]. The approved location for the quinoxaline
ring system is shown in Fig. 1, where 2 and 3 are designated a-
positions [2]. They are important in industry due to their ability to
inhibit the metal corrosion [3e5], in the preparation of the por-
phyrins, since their structure is similar to the chromophores in the
natural system, and also in the electroluminescent materials [6]. In
pharmacological industry, they have absorbed a great deal of
attention due to their wide spectrum of biological properties
[1,7e10]. For example, they can be used against bacteria, fungi,
virus, leishmania, tuberculosis, malaria, cancer, depression, and
neurological activities, among others. The quinoxaline structural
nucleus renders all these activities possible. Quinoxaline structureacts as a precursor to assembly a large number of new compounds
for diverse applications [1].
Quinoxaline is formed by the fusion of two aromatic rings,
benzene and pyrazine. For this reason is also called benzopyrazine,
and is described as a bioisoster of quinoline, naphthalene and
benzothiophene [11]. The atoms S and N play an important role in
the ring since they stabilize ion radical species. Molecular weight of
the quinoxaline is 130.15, with a molecular formula of C8H6N2, and
it is a white crystalline powder, at standard conditions [1].
Chemically, quinoxaline is a low melting solid, purified by
distillation, and a fraction of boiling point 108e111/12 mm has a
melting point 29e30 C [2,11]. Quinoxalines are soluble in water,
and produces monoquaternary salts when treated with quater-
nizing agents, like dimethyl sulfate and methyl p-toluene sulpho-
nate. The quaternary salts of 2-alkylquinoxalines are unstable and
converted into complex colored products by oxidation [2]. It is
acidic with a pKa of 0.60 inwater at 20 C, and nitration occurs only
under forcing conditions (Conc. HNO3, Oleum, 90 C), resulting in
the formation of two compounds: 5-nitroquinoxaline (1.5%) and
5,7-dinitro-quinoxaline (24%) [11]. Its second pKa is 5.52 indi-
cating that quinoxaline is significantly diprotonated in a strongly
acidic medium [2].
Fig. 1. Quinoxaline.
Fig. 3. 8-Chloro-1,4-substituted[1,2,4]triazolo[4,3-a] quinoxaline derivatives core.Quinoxaline has a dipole moment of 0.51 Debye, and their first
and second ionization potentials, measured by photon electron
spectroscopy, are 8.99 and 10.72 eV, respectively [2]. However, it is
not clear that the first electron is lost from which orbital, since
highest-occupied p-orbital and non-bonding orbitals are very close
in energy. The heat of aromatizationwas calculated to be 79.739 eV
using a self-consistent field molecular orbital treatment [2]. The
molecular orbital calculations of thep electron density showed that
the higher the electron density on the carbon ring is in positions 5
and 8, followed by the C-6 and C-7 positions, and the lower C-2 and
C-3 positions. [2].
Most of quinoxaline derivatives are synthetic and natural qui-
noxaline derivatives are rare [12], such as echinomycin and triostin-
A. The common procedure for their synthesis consists of
condensing o-disubstituted benzene with a two carbon synthon.
Therefore, the condensation of o-phenylenediamine with a-dicar-
bonyl compounds results in quinoxaline formation (Fig. 2) [2].
Numerous methods are available for the synthesis of quinoxa-
line derivatives which involve condensation of 1,2-diamines with
a-diketones [13], 1,4-addition of 1,2-diamines to diazenylbutenes
[14], cyclizationeoxidation of phenacyl bromides [15] and oxida-
tive coupling of epoxides with ene-1,2-diamines [16]. Recent
research groups have presented reports concerning the synthesis of
different quinoxaline derivatives involving several green method-
ologies, including recyclable catalysts, microwave-assisted syn-
thesis and reactions in aqueous medium [17].
Quinoxaline and its derivatives could be converted in bothmono
and di-N-oxides by oxidation with peracids [2].2. Biological activity
The study of quinoxaline and its derivatives has become a sub-
ject of interest in recent years due to their wide variety of biological
activities as well as therapeutic applications. Since they are rare in
nature, synthetic quinoxalines are included in various antibiotics
such as echinomycin, levomycin and actinomycin, well-known to
inhibit the growth of Gram-positive bacteria and are also active
against transplant tumors [11,18].Echinomycin, for example have
quinoxalinyl moiety in their structure and also some known drugs,
like Brimonidins, alleviates glaucoma symptoms [1].
The vast scope of synthesized quinoxaline and derivatives po-
tential is well referenced and published in a wide range of scientific
journals. Scientific data concerning the potential relevance of qui-
noxaline and derivatives in the literature were analyzed.Fig. 2. Quinoxalin2.1. Antimicrobial activity
The antimicrobial resistance is a serious threat to global public
health, as a result of the widely disseminated and careless use of
antimicrobials [19], and demands a continuous effort in order to
seek for better antimicrobial agents, effective against resistant
pathogenic microorganisms [11,20e22]. There are a wide range of
quinoxaline derivatives with antimicrobial activity documented
[22].
2.1.1. Antibacterial activity
A new series of 8-chloro-1,4-substituted[1,2,4]triazolo[4,3-a]
quinoxaline derivatives (Fig. 3), being the substituents R and R0
listed in Table 1, was synthesized and screened for antimicrobial
and antioxidant activities [23]. The antibacterial activity was
screened against Gram-positive Staphylococcus aureus and Bacillus
subtilis, and Gram-negative Proteus vulgaris and Klebsiella pneu-
moniae, using chloramphenicol as reference drug [21].
Ammar et al [24], have synthesized thieno[2,3-d]pyrimidines
and pyrrolo[3,4-b]quinoxalines which antibacterial activity was
tested against S. aureus and Escherichia coli.
2.1.2. Antitubercular activity
Mycobacterium is a particular bacteria that is responsible for a
contagious disease, an infection called Tuberculosis (TB), caused by
Mycobacterium tuberculosis. This disease has a high rate ofmortality
in the world. About 3 million people die every year from TB, and 8
million new cases are estimated each year, which 95% of them occur
in developing countries [25].
The therapy used in these days to fight TB consists in the
administration of one of three drugs (isoniazid, rifampin or pyr-
azinamide) for 2 months, followed by 4 months of follow-up
therapy with isoniazid and rifampin. However, due to the arising
of multidrug resistant (MDR) TB it is required the development of
new therapeutic agents, with a uniquemechanism of action, able to
treat MDR forms of the disease [26].
Several studies have been described, concerning synthesis and
biological activity of a large amount of quinoxalines and 1,4-di-N-
oxide quinoxaline derivatives, where compounds such as 7-chloro-
3-(p-substituted)-phenylaminoquinoxaline-2-carbonitrile-1,4-di-
N-oxide, 6,7-dichloro-2-ethoxycarbonyl-3-methylquinoxaline-1,4-
di-N-oxide and 3-acetamide-6,7-dichloroquinoxaline-2-
carbonitrile-1,4-di-N-oxide derivatives have been shown toe synthesis.
possess M. tuberculosis growth inhibition values from 99 to 100%
[21,27]. However, it is observed that the lack of the two N-oxide
groups lead to the loss of the antimycobacterial activity [27,28].
Some novel condensed bridgehead nitrogen heterocycles of
quinoxalines have been synthesized and activity against
M. tuberculosis H37Rv species was obtained [11,21,29]. The com-
pound 3-methyl-2-phenylthioquinoxaline-1,4-dioxide generally
presented a good activity againstM. tuberculosis in the preliminary
in vitro evaluation and exhibited Minimum Inhibitory Concentration
(MIC) between 0.39 and 0.78 mg mL1 (rifampicin
MIC ¼ 0.25 mg mL1) [7]. The MIC is defined as the lowest con-
centration of an antimicrobial that inhibits the visible growth of a
microorganism after overnight incubation. The range of antibiotic
concentrations used for determining MICs is universally accepted
to be in doubling dilution steps up and down from 1 mg/L as
necessary [30].
A new class of anti-infective agents against MDRM. tuberculosis,
with no cytotoxicity reported was presented and includes 3-
methyl-9-substituted-6-oxo-6,9-dihydro-3H-(1,2,3)-triazolo[4,5-h]
quinolone-carboxylic acids and their esters [31].
2.1.3. Antiviral activity
Viruses are small infectious agents that replicate only inside the
living cells of an organism and can infect all types of organisms,
from animals and plants to bacteria [32].
Viruses such as Herpes simplex virus type 1 (HSV-1) and type 2
(HSV-2) belong to the Herpesviridae family, are double-stranded
DNA [33], and share high homology in genome structure and
DNA sequence. These viruses can cause various illnesses states from
asymptomatic infection to fulminant disseminated diseases,
including labials herpes, keratitis (cornea inflammation), genital
herpes, and encephalitis [34].
There are a wide number of drugs for treatment of HSV in-
fections like acyclovir, ganciclovir, penciclovir, valaciclovir (con-
verted to acyclovir) and famciclovir (converted to penciclovir)
[33,35], being acyclovir the most common drug used. However,
there are drug-resistant strains of HSV emerging and increasing
[33,36], leading to the search of new antiviral drugs.
Quinoxalines have a variable antiviral activity, suggesting that
their activity depends on specific substitution patterns. Novel series
of al 6H-indolo-[2,3-b]quinoxalines were synthesized and evalu-
ated for antiherpes virus activity and the compound 2,3-
dimethyl(dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline had
the major antiviral activity. This specific compound was tested for
its antiviral effect and action mechanism, showing the capacity to
inhibit replication of HSV-1, cytomegalovirus, and varicellaezoster
virus in tissue culture, in concentrations of 1e5 mM, depending on
the virus amount and cell type used in the assay. Also the com-
pound 2,3-dimethyl-6-(dimethylaminoethyl)-6H-indolo-(2,3-b)
quinoxaline (Fig. 4) presented high activity against HSV, and de-
rivatives with 6-(2-dimethylaminoethyl) side chain, due to their
DNA binding properties, showed an improved biological activity
[1].
There is also reference to IndQloquinoxalines(2,3-dimethyl-6-
(dimethylaminoethyl)-6H-indolo[2,3-b]-quinoxaline) with capac-
ity to inactivate virions in high concentrations (around 300 mM),
and decrease the synthesis of viral DNA and protein at lower con-
centrations (around 3 mM) [21].
Concerning human immunodeficiency virus type 1 (HIV-1),
which is the agent causative of acquired immunodeficiency syn-
drome (AIDS) [37], there are awide number of clinical drugs used to
fight the disease, such as non-nucleoside reverse transcriptase (RT)
inhibitors, which interact with a specific allosteric non-substrate
binding site on HIV-1 RT [11]. Compound 6-chloro-3,3-dimethyl-
4-isopropenyloxycarbonyl-3,4-dihydroquinoxalin-2-[1H]-thione(Fig. 5) was synthesized and evaluated for enzyme activity, and was
found to be a very potent inhibitor for both HIV-1 RT activity and
HIV-1 replication in tissue cultures. Although, like some other non-
nucleoside RT inhibitors, this compound was not effective against
human immunodeficiency virus type 2 (HIV-2 RT) [21].
Also, an in vitro fluorescence polarization assay demonstrated
that a library of quinoxaline derivatives, prepared to target non-
structural protein 1 of influenza A (NS1A), disrupted the
dsRNAeNS1A interaction to varying extents, which lead to the
development of anti-influenza drugs [38].
In this study, investigators have prepared a library based on 2,3-
difuryl-4-quinoxaline-R-metilcarboxamide derivatives (Fig. 6),
with 2-furyl groups at position 2 and 3 and phenyl group in position
6 through an amide linker. Among all the compounds in the library,
compounds listed in Table 1 have shown the highest effectiveness,
being the R the possible substituents. These compounds do not
inhibit NS1AedsRNA interactions by interfering with dsRNA but by
the binding to NS1A dsRNA-binding domain itself. Also, the com-
pound 2 was able to inhibit influenza A virus growth [38].
2.1.4. Antifungal activity
Prevalence of fungal diseases has increased significantly in the
past 50 years. Fungal diseases manifest themselves differently,
including mycoses in the skin, hair, nails, but also as systemic
mycoses, being the last one an issue of greatmedical concern due to
the increase in the immunocompromised patient population [39].
One of themost common fungal infections is candidiasis, caused
by Candida albicans, a diploid fungus that grows both as yeast and
filamentous cells [40]. This fungus can also develop resistance to
antimycotic drugs that already exist in the market [41], being
important a constant search for new drugs and treatments.
Thieno[2,3-d]pyrimidines and pyrrolo[3,4-b]quinoxalines were
synthesized and tested against C. albicans, and presented antifungal
activity [11,24].
Researchers also reported some 2-sulphonylquinoxalines and 3-
[(alkylthio)methyl]quinoxaline-1-oxide derivatives as compounds
with high antifungal activity [7], and also pyrazoloquinoxalines
which were observed to be active against fungal infections [1].
2.1.5. Antiprotozoan activity
2.1.5.1. Antiamoebic activity. Entamoeba histolytica is a protozoan
responsible for the amoebiasis infection [42], causing amoebic co-
litis, brain and liver abscess, being an important leading cause of
death worldwide. The traditional treatment used is based in anti-
amoebic compounds such as nitroimidazoles, but not always
effective, raising the possibility of drug resistance, leading to the
search of new compounds able to fight the infection successfully
[43].
Some 1-[thiazole[4,5-b]quinoxaline-2-yl]-3-phenyl-2-pyrazolines
derivatives produced (Fig. 7), were found to be a potent inhibitor
of HM1:IMSS strain of E. histolytica, where the presence of 3-bromo
or 3-chloro substituents on the phenyl ring and 4-methyl group
on the pyrazoline ring affected antiamoebic activity to a great extent
[43].
2-Cyano-3-(4-phenylpiperazine-1-carboxamido)quinoxaline
1,4-dioxide derivatives have also presented activity against Leish-
mania, but were not effective against Plasmodium [44].
In such study metronidazole was used as the reference drug and
had a 50% inhibitory concentration of IC50 1.69e1.82 mM, and
compound 5 with 3-bromo and 4-methyl substitution, and com-
pound 6 with 3-chloro and 4-methyl substitution on pyrazoline
ring (Table 1), showed great effectiveness, being the most actives,
presenting IC50 1.45 mM and IC50 0.72 mM, respectively [43]. In
Table 1, the positions 3 and 4 are represented by R and R0.
Table 1
Published experimental data (percentage of binding, intercalation, IC50 and IG50) of quinoxaline derivatives and their substituents.
Main compound Compound R R0 R00 % binding
at 50 mM
% intercalation
at 50 mM
IC50 mM IG50 mM Reference
8-Chloro-1,4-substituted
(1,2,4)triazolo[4,3-a]
quinoxaline derivatives
1 eCl e e e e e 21
2 eSCH2COOH e e e e e
3 eOMe e e e e e
4 eSCH2COOH e e e e e
5 eCl e e e e e
6 e e e e e
7 e e e e e
8 eC3H7 e e e e e
9 eSCH2COOH e e e e e
10 e e e e e
2,3-Difuryl-4-quinoxaline (R)
metilcarboxamidederivatives
1 3-O-Me-Ph- e e 74.0 4.5 6.2 e 38
2 2-Furyl- e e 79.5 5.9 3.5 e
1-[Thiazolo[4,5-b]cquinoxaline-
2-yl]-3-phenyl-2-pyrazolines
derivatives
1 He He e e e 6.76 e 43
2 Bre He e e e 4.98 e
3 Cle He e e e 1.09 e
4 He H3Ce e e e 2.34 e
5 Bre H3Ce e e e 1.45 e
6 Cle H3Ce e e e 0.72 e
Metronidazole e e e e e 1.69 e
2-Alkylcarbonyl and 2-benzoyl-
3-trifluromethylquinoxaline-1,
4-di-N-oxide derivatives
1 He He e e e e 1.02 8
2 Cle Cle e e e e 0.42
3 Fe Fe e e e e 0.52
4 Fe Fe e e e e 0.15
5 He He e e e e 0.49
6-Arylamino-2,3-bis(pyridin-
2-yl)-7-chloro-quinoxaline
5,8-diones
1 He Cle He e e 1.5 e 58
2 He HOe He e e 5.5 e
3 He Fe He e e 1.0 e
4 He F3Ce He e e 1.1 e
5 He F3COe He e e 1.0 e
6 He H3COe He e e 3.5 e
7 He He He e e 3.1 e
8 Cle Cle He e e 1.0 e
9 Fe Fe Fe e e 1.2 e
10 e e e e e >100 e
MPA e e e e e 1.0 e
Table 1 (continued )
Main compound Compound R R0 R00 % binding
at 50 mM
% intercalation
at 50 mM
IC50 mM IG50 mM Reference
8-Chloro-1,4-substituted(1,2,4)
triazolo[4,3-a] quinoxaline
derivatives
1 eCl e e e e e 20
2 eSCH2COOH e e e e e
3 eOMe e e e e e
4 eSCH2COOH e e e e e
5 eCl e e e e e
6 e e e e e
7 e e e e e
8 eC3H7 e e e e e
9 eSCH2COOH e e e e e
10 e e e e e
2,3-Difuryl-4-quinoxaline (R)
metilcarboxamidederivatives
1 3-O-Me-Ph- e e 74.0 4.5 6.2 e 35
2 2-Furyl- e e 79.5 5.9 3.5 e
1-[Thiazolo[4,5-b]cquinoxaline-
2-yl]-3-phenyl-2-pyrazolines
derivatives
1 He He e e e 6.76 e 40
2 Bre He e e e 4.98 e
3 Cle He e e e 1.09 e
4 He H3Ce e e e 2.34 e
5 Bre H3Ce e e e 1.45 e
6 Cle H3Ce e e e 0.72 e
Metronidazole e e e e e 1.69 e
2-Alkylcarbonyl and 2-benzoyl-
3-trifluromethylquinoxaline-1,
4-di-N-oxide derivatives
1 He He e e e e 1.02 8
2 Cle Cle e e e e 0.42
3 Fe Fe e e e e 0.52
4 Fe Fe e e e e 0.15
5 He He e e e e 0.49
6-Arylamino-2,3-bis(pyridin-2-yl)-
7-chloro-quinoxaline 5,8-diones
1 He Cle He e e 1.5 e 54
2 He HOe He e e 5.5 e
3 He Fe He e e 1.0 e
4 He F3Ce He e e 1.1 e
5 He F3COe He e e 1.0 e
6 e H3COe He e e 3.5 e
7 He He He e e 3.1 e
8 Cle Cle He e e 1.0 e
9 Fe Fe Fe e e 1.2 e
10 e e e e e >100 e
MPA e e e e e 1.0 e
Fig. 5. 6-Chloro-3,3-dimethyl-4(isopropenyloxycarbonyl)-3,4-dihydroquinoxalin-2(1H)-
thione.
Fig. 7. 1-[Thiazolo[4,5-b]quinoxaline-2-yl]-3-phenyl-2-pyrazolines core.
Fig. 4. 2,3-Dimethyl-6-(dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline.2.1.5.2. Antiparasitic activity. Leishmaniasis is a parasitic disease
cause by protozoan of the genus Leishmania in tropical and sub-
tropical areas of the World, and despite all efforts to fight this
disease about 1e2 million new cases are registered every year
[21,45]. Most of the drugs available against leishmaniasis are
expensive and require a long treatment and are becomingmore and
more ineffective [9].
Malaria is also a tropical parasitic disease, cause by Plasmodium
falciparum, leading to over a million deaths annually, and rising,
probably due to a resistance increasing, requiring the development
of cheaper and more effective drugs [46,9,47].
Recently, 14 new 3-amino-1,4-di-N-oxide quinoxaline-2-
carbonitrile derivatives were synthesized. These compounds were
evaluated for their in vitro antimalarial and antileishmanial activityFig. 6. 2,3-Difuryl-4-quinoxaline(R)metilcarboxamide derivatives.against P. falciparum (Colombian FCR-3 strain) and Leishmania
amazonensis (strain MHOM/BR/76/LTB-012A). The study showed
that compounds with one halogenous group in position 6 and 7
provide an efficient approach for further development of antima-
larial and antileishmanial agent.
Growth inhibition of some quinoxaline N,N-dioxide derivatives
and related compounds against Trypanosoma cruzi was reported.
Results evidence a structure-activity relationship, expressing
important cross-correlation between the descriptors used (physi-
cochemical properties, biological activity and liposolubility) [48].
2.2. Chronic and metabolic disease bioactivity
Besides antimicrobial activity, quinoxaline derivatives have
shown innumerous applications regarding the treatment of several
chronic and metabolic diseases, such as cancer, diabetes, neuro-
logical disorders, atherosclerosis and inflammation. These condi-
tions will be explored in the next sections.
2.2.1. Diabetes
Diabetes Mellitus is a disease caused by the dysfunction of
glucose homeostasis, inwhich glucose levels appear abnormal with
tendency to hyperglycemia. Diabetes type 1 is insulin-dependent
and requires a daily subcutaneous injection of insulin, while dia-
betes type 2 is non-insulin-dependent and can be treated with
several drugs such as sulfonylureas, nateglinide, and biguanides,
among others [10,49]. However these treatments have limited ef-
ficacy and tolerability, and could cause severe side effects [49]. In
this regard, new transition metal complexes of quinox-
alineethiosemicarbazone ligands L1H2 and L2H2 (Fig. 8) were pre-
pared. The ligands were explored with copper and zinc complexes
in diabetes induced Wister rats. The compounds [ZnL1(H2O)] and
L2H2 have showed prominent reduction in blood glucose level andFig. 8. Ligands L1H2 and L2H2. For L1H2, R ¼ CH3 and for L2H2, R ¼ C6H5.
Fig. 10. Compounds 1e5.
Fig. 11. Alphagan chemical structure.
Fig. 9. (N-arylcarbamoyl and N-arylthiocarbamoyl) hydrazinequinoxalin-2(1H).the complexes [CuL1(H2O)], [ZnL1(H2O)] and [CuL2(H2O)] have
exhibited good activity in oral glucose tolerance test (OGTT) and
showed low toxicity [10].
Also (N-arylcarbamoyl and N-aryl thiocarbamoyl)hydrazine-
quinoxalin-2-(1H) (Fig. 9) have been reported as mild hypo-
glycaemic agents [1].
2.2.2. Chronic inflammation
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used in therapeutics, generally for the treatment of the pain and
inflammation. Nevertheless its long-term usage can lead to signif-
icant side effects like gastrointestinal lesions, bleeding, and neph-
rotoxicity. Due to the reasons mentioned it is important the
discovery of new safer anti-inflammatory drugs [50,51].
Quinoxaline 1,4-di-N-oxide derivatives such as 4-(7-fluoro-3-
methyl-quinoxalin-2-yl)-6-(3,4,5-trimethoxy-phenyl)-pyrimidin-
2-ylamine and 2,6,7-trimethyl-3-[5-(3,4,5-trimethoxy-phenyl)-
4,5-dihydro-1H-pyrazol-3-yl]-quinoxaline, showed an in vivo anti-
inflammatory effect, higher than one reference drug, IMA (indo-
methacin), and in vitro decreasing values of LOX (lipoxygenase).
LOX is an enzyme essential to arachidonic acid (AA) metabolism,
which leads to the formation of leukotrienes, a type of pro-
inflammatory mediator involved in processes like fever, asthma
and cardiovascular disease [52]. It was demonstrated that the
incorporation of pyrimidine, thiazolopyrimidine, pyrazolopyridine,
pyridopyridine, p-chlorophenyl, p-methoxyphenyl or pyridine nu-
cleus to quinoxaline moiety cause significant anti-inflammatory
activity, and also analgesic [50].
4-Alkoxy-6,9-dichloro[1,2,4]triazolo[4,3-a]quinoxalines were
also synthesized and anti-inflammatory activity was tested as in-
hibitors of the pro-inflammatory cytokines TNF-a and IL-6 [53].
Results revealed efficiency in both cytokines was demonstrated.
2.2.3. Cancer
Quinoxaline nucleuses exhibit potential anticancer activity,
which makes them an important basis for the anticancer drugs
[21]. A new series of 2-alkylcarbonyl and 2-benzoyl-3-
trifluromethylquinoxaline-1,4-di-N-oxide derivatives was synthe-
sized and evaluated for in vitro antitumor activity against a 3-cell
line panel (MCF7 (breast), NCIH 460 (lung) and SF-268 (CNS)),
and then evaluated in full panel of 60 human tumor cell lines,
derived from nine cancer cell types. It was showed that, in general,
anticancer activity depends on the substituents in the carbonyl
group, increasing the activity in the order: ethyl < isopropyl < tert-
butyl < phenyl-ones. Among these the compounds (Fig. 10) 2-
(3-methylbut-1-en-2-yl)-3-(trifluoromethyl)quinoxaline-1,4-di-
N-oxide (Compound 1), 2-benzoyl-6,7-dichloro-3-trifluoromethyl-
quinoxaline 1,4-di-N-oxide (Compound 2), their difluor-
inatedanalogs(6,7-difluoro-2-isobutyryl-3-trifluoromethylquinox-aline 1,4-di-N-oxide and 2-benzoyl-6,7-difluoro-3-trifluoromethyl-
quinoxaline 1,4-di-N-oxide) (Compound 3 and 4), and 2-(2,2-
dimethylpropanoyl)-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide
(Compound5) were the most active, with higher anticancer activity
with mean GI50 (Growth Inhibition) values of 1.02, 0.42, 0.52, 0.15,
and 0.49 mM, respectively (Table 1) [8,21]. The possible substituents
of these compounds are presented in Table 1, represented by R and
R0.
Fig. 12. 6-Arylamino-2,3-bis(pyridin-2-yl)-7-choloroquinoxaline-5,8-diones.2.2.4. Glaucoma
Glaucoma is the designation to refer the diseases that affect the
optic nerve, involving the loss of retinal ganglion cells in a char-
acteristic pattern of optic neuropathy, and excavations of the nerve
head [54]. Almost 67 million people worldwide are affected by
glaucoma, remaining one of the causes of irreversible blindness,
responsible for 8% of blindness after cataract [55].
Alphagan® (Brimonidin) is a relatively selective alpha-2 adren-
ergic receptor agonist, and its composition consists in (5-bromo-N-
(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxaline (Fig. 11). This drug
works as an antiglaucoma agent, due to its power to reduce the
intraocular pressure, alleviating the symptoms of glaucoma [1,21].2.2.5. Atherosclerosis
Atherosclerosis is responsible for 50% of all mortality in the USA,
Europe and Japan, is the principal cause of heart attack, stroke and
gangrene of the extremities [56]. After artery injury, abnormal
proliferation andmigration of vascular smooth cells (SMCs) into the
intimal layer of the arterial wall occurs, proliferating and synthe-
sizing extracellular matrix components, playing an important role
in coronary artery atherosclerosis and restenosis after an angio-
plasty [57].
A series of 6-arylamino-2,3-bis(pyridin-2-yl)-7-choloroquino-
xaline-5,8-diones (Fig. 12) were synthesized and screened for
their inhibitory activity on rat aortic smooth muscle cell (RAoSMC)
proliferation. Possible substituents of this compound are repre-
sented in Table 1 by R, R0 and R00. IC50 (Inhibition Concentration)
values were determined and compared to the positive control
mycophenolic acid (MPA) (Table 1), and most of the compounds
showed good activity, and the quinoxaline-5,8-diones were found
as potent antiproliferative agents [1,21,58].
Quinoxaline derivatives were also tested as specific inhibitors
for cancer cells survival, by inhibition of transglutaminase 2 (TGase
2). This enzyme as an important role both in pro-survival and anti-
apoptosis during oncogenesis [59].2.2.6. Neurological disorders
5-Hydroxytryptamine (5HT), commonly known as serotonin, is
a neurotransmitter involved in a great number of physiological and
patho-physiological processes, acting through the receptor sub-
types, from 5-HT1to 5-HT7. Almost all of the receptors subtypes
belong to the family of G-protein coupled receptor (GPCR), but the
specific receptor subtype 5HT3 is a ligand gated ion channel [60,61].
The antagonists to this receptor lead to various responses, such as
anti-emetic action in cancer chemo-/radio-therapy induced nausea
and vomiting, anti-depressant, anxiolytic, anti-psychotic and anti-
inflammatory. However, the drugs available to depression condi-
tions have a delayed onset of action, which emphasizes the demand
of new antidepressant drugs, with a safer and faster action [60,61].New series of structurally novel 3-substituted-2-carboxamides
quinoxaline were designed as 5-HT3 receptor antagonists using
ligand-based approach. All the compounds synthesized exhibited
5-HT3 receptor antagonism, and some of them showed antagonism
greater than the standard drug, ondansetron, like [3-
ethoxyquinoxalin-2-yl][4-methylpiperazin-1-yl]-methanone and
N-[2-(1H-indol-3-yl)ethyl]-3-ethoxyquinoxaline-2-carboxamide
[61]. The compound N-3-methoxyquinoxalin-2-carboxamide
showed the most favorable 5-HT3 receptor antagonism [21].
Also 3-benzyl-2-substituted quinoxalines were synthesized as
novel monoamine oxidase A (MAO-A) inhibitors. The MAO in-
hibitors are very useful for the treatment of several neurological
diseases, like Parkinson and depression. MAO-A inhibitors are used
as antidepressant and antianxiety drugs. In this study, the final
compounds were evaluated for their MAO-A inhibitory activity
in vitro, using serotonin as substrate [11].
2.2.7. Anti glutameric activity
Glutamate, an excitatory amino acid (EAA), is a major excitatory
neurotransmitter in the central nervous system in mammalian
species. Although, if a overstimulation of the postsynaptic gluta-
mate receptors occurs due to a high release of EAA, could result in
neuronal death, and consequently induce neurodegenerative dis-
orders such as Alzheimer and Huntington's disease [62]. AMPA-R
(a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid recep-
tor) antagonists have showed to have no side effects such as
schizophrenia and protective activity in neural death, and many
quinoxalinedione derivatives with competitive AMPA-R antago-
nistic activity have been synthesized and tested against the EAA
receptor [63].
The compound 7-[[4-[N-[4-carboxyphenyl]carbamoyloxy]
methyl]imidazolyl]-3,4-dihydro-6-nitro-3-oxo-quinoxaline-2-car-
boxylic acid (GRA-293) was identified as a novel AMPA-R antago-
nist due to its high potency and good selectivity in vitro, and its
potent neuroprotective effects in an animal model in vivo, higher
than the known quinoxalinedione compounds used. These effects
are due to a novel substituent, namely substituted benzene ring
with urethane linkage to imidazole, in C-7 position, which leads to
a potent AMPA-R affinity and contributes to therapeutic efficacy in
animal models. This compound, with such characteristics, meets
the criteria, in an injectable formulation, for use in the treatment of
acute cerebral ischemia [63].
3. Conclusions
The literature survey reveals that quinoxaline and their de-
rivatives have a vast application, with a great potential, being an
important class of biological active compounds. Quinoxaline and its
derivatives showed awide field of application inmedicine due to its
biological activities, which include antimicrobial, antidiabetic,
antiproliferative, anti-inflammatory, anticancer, antiglaucoma, an-
tidepressant activities and also with AMPA-R antagonist activity.
The biological activities referred are very encouraging for the in-
vestigators and pharmacists, leading to new treatments and ther-
apeutic agents that will benefit humanity.
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